High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry

The aim of this retrospective study was to assess toxicity and efficacy of adjuvant high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (AHSCT) in 583 high-risk breast cancer (BC) patients (>3 positive nodes) who were transplanted between 1995 and 2005 in Europe. All patients received surgery before transplant, and 55 patients (9.5%) received neoadjuvant treatment before surgery. Median age was 47.1 years, 57.3% of patients were premenopausal at treatment, 56.5% had endocrine-responsive tumors, 19.5% had a human epidermal growth factor receptor 2 (HER2)-negative tumor, and 72.4% had ≥10 positive lymph nodes at surgery.

Source: Biology of Blood and Marrow Transplantation - December 23, 2015 Category: Hematology Authors: Massimo Martino, Francesco Lanza, Lorenzo Pavesi, Mustafa Öztürk, Didier Blaise, Rubén Leno Núñez, Harry C. Schouten, Alberto Bosi, Ugo De Giorgi, Daniele Generali, Giovanni Rosti, Andrea Necchi, Andrea Ravelli, Carmelo Bengala, Manuela Badoglio, Pao Source Type: research